<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calculator: Khorana score for estimating venous thromboembolism risk in adults with cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calculator: Khorana score for estimating venous thromboembolism risk in adults with cancer</h1>
<div class="utdArticleSection" id="topicContentCalculator"><div id="topicText">
<div id="mc3k">
<form action="" id="KhoranaScore_form" name="KhoranaScore_form" onreset="rrclr(); document.getElementById('inputchk').innerHTML=inputchktxt; " onsubmit="return false;">
<table cellpadding="4" cellspacing="0" summary="EBMcalc Table" width="100%">
<tbody><tr><td bgcolor="#eeeeee" width="1%"><br/></td>
<td align="left" bgcolor="#eeeeee">
<span class="medCalcFontTitleBox">

 
Calculator: Khorana score for estimating venous thromboembolism risk in adults with cancer
</span></td></tr></tbody></table><br/> <br/>
<div id="calc_main">
<div id="calc_input">
<center>
<table cellpadding="3" cellspacing="0" summary="EBMcalc Table">
<tbody><tr><td align="left" colspan="3"><span class="medCalcFontCCTabBold">Site of primary tumor </span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: Site of primary tumor. The option is Very high risk (stomach, pancreas) (2 points)" id="togel1" name="cc1" onclick="KhoranaScore_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel1');">Very high risk (stomach, pancreas) (2 points)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: Site of primary tumor. The option is  High risk (lung, lymphoma, gynecologic, bladder, testicular) (1 point)" id="togel2" name="cc1" onclick="KhoranaScore_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel2');"> High risk (lung, lymphoma, gynecologic, bladder, testicular) (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: Site of primary tumor. The option is All other sites (0 points)" id="togel3" name="cc1" onclick="KhoranaScore_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel3');">All other sites (0 points)</span></td></tr>
<tr><td align="left" colspan="3"><span class="medCalcFontCCTabBold">Laboratory results and BMI</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate Prechemotherapy platelet count ≥350,000/microL [≥350 X 10&lt;sup&gt;9&lt;/sup&gt;/L] (1 point)" id="togel4" name="cc2" onclick="KhoranaScore_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel4');">Prechemotherapy platelet count ≥350,000/microL [≥350 X 10<sup>9</sup>/L] (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate Hemoglobin level &lt;10 g/dL [&lt;100 g/L] or use of ESAs (1 point)" id="togel5" name="cc3" onclick="KhoranaScore_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel5');">Hemoglobin level &lt;10 g/dL [&lt;100 g/L] or use of ESAs (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate Prechemotherapy WBC &gt;11,000/microL [≥11 X 10&lt;sup&gt;9&lt;/sup&gt;/L] (1 point)" id="togel6" name="cc4" onclick="KhoranaScore_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel6');">Prechemotherapy WBC &gt;11,000/microL [≥11 X 10<sup>9</sup>/L] (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate BMI ≥35 kg/m&lt;sup&gt;2&lt;/sup&gt; (1 point)" id="togel7" name="cc5" onclick="KhoranaScore_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel7');">BMI ≥35 kg/m<sup>2</sup> (1 point)</span></td></tr>
</tbody></table>
<span class="medCalcFontOne" id="inputchk"><br/> <br/><b>Important:</b> Inputs must be complete to perform calculation. <br/></span>
</center>
</div>
<br/> <br/>
<div id="calc_result">
<span class="medCalcFontCCTabBold">
Total criteria point count:
</span>
<input aria-label="This box holds the total criteria point count" aria-readonly="true" name="cctotal" size="6" type="text"/><br/> <br/>
<center><input name="reset" type="reset" value="Reset form"/> </center>
<br/> <br/>
<div aria-label="This table highlights the result Incidence of VTE based on Khorana score. No result is highlighted" id="rr1_tag" tabindex="0">
<table cellpadding="4" cellspacing="0" summary="EBMcalc Table" width="100%">
<tbody><tr><td bgcolor="#eeeeee" width="1%"><br/></td>
<td align="left" bgcolor="#eeeeee">
<span class="medCalcFontTitleBox">


Incidence of VTE based on Khorana score
</span></td></tr></tbody></table><br/> <br/>
</div>
<center>
<table border="1" cellpadding="4" cellspacing="0" summary="RRTable">
<tbody><tr bgcolor="#ffffff">
<td align="center"><span class="medCalcFontOneBold"> Khorana score points</span></td>
<td align="center"><span class="medCalcFontOneBold">Risk</span></td>
<td align="center"><span class="medCalcFontOneBold">Derivation cohort<sup>[1]</sup> VTE risk after 2.5 months</span></td>
<td align="center"><span class="medCalcFontOneBold"> Validation cohort<sup>[1]</sup> VTE risk after 2.5 months</span></td>
<td align="center"><span class="medCalcFontOneBold"> Independent cohort<sup>[2]</sup> VTE risk after 6 months</span></td>
<td align="center"><span class="medCalcFontOneBold"> Patients in phase I trials<sup>[3]</sup> VTE risk after 2 months</span></td>
</tr>
<tr id="rr1_1"><td align="center" nowrap="nowrap"><span class="medCalcFontOneBold"> 0</span></td>
<td align="center"><span class="medCalcFontOne"> Low</span></td>
<td align="center"><span class="medCalcFontOne">0.8%</span></td>
<td align="center"><span class="medCalcFontOne">0.3%</span></td>
<td align="center"><span class="medCalcFontOne">1.5%</span></td>
<td align="center"><span class="medCalcFontOne">1.5%</span></td>
</tr>
<tr id="rr1_2"><td align="center" nowrap="nowrap"><span class="medCalcFontOneBold"> 1 to 2</span></td>
<td align="center"><span class="medCalcFontOne"> Intermediate</span></td>
<td align="center"><span class="medCalcFontOne">1.8%</span></td>
<td align="center"><span class="medCalcFontOne">2%</span></td>
<td align="center"><span class="medCalcFontOne">3.8% (1 point); 9.6% (2 points)</span></td>
<td align="center"><span class="medCalcFontOne">4.8%</span></td>
</tr>
<tr id="rr1_3"><td align="center" nowrap="nowrap"><span class="medCalcFontOneBold"> 3 to 6</span></td>
<td align="center"><span class="medCalcFontOne"> High</span></td>
<td align="center"><span class="medCalcFontOne">7.1%</span></td>
<td align="center"><span class="medCalcFontOne">6.7%</span></td>
<td align="center"><span class="medCalcFontOne">17.7%</span></td>
<td align="center"><span class="medCalcFontOne">12.9%</span></td>
</tr>
</tbody></table>
</center>
<br/> <br/>
</div>
</div>
<div id="calc_notes">
<span class="medCalcFontOneBold">Notes</span>
<ul class="medCalcFontOne">
<li>The Khorana score was developed from a cohort of 2701 patients with cancer receiving a first course  of chemotherapy to predict the cumulative incidence of VTE at 2.5 months.<sup>[1]</sup> The score was  validated in a cohort of 1365 patients, most of whom (91%) had an ECOG performance status of 0 or 1.<sup>[1]</sup></li>
<li>The score was tested independently in 819 patients with newly diagnosed cancer or cancer progression  who had not received chemotherapy within the preceding 3 months to predict the cumulative incidence of  VTE at 6 months,<sup>[2]</sup> and in 1415 patients enrolled in phase I clinical trials followed for a  median of 2 months.<sup>[3]</sup></li>
<li>BMI: body mass index; ESAs: erythropoiesis-stimulating agents; WBC: white blood count; BMI: body mass index; VTE: venous thromboembolism; ECOG: Eastern Cooperative Oncology Group.</li>
</ul>
</div>
<br/> <br/>
<div id="calc_refs">
<span class="medCalcFontRef"><b>References</b></span>
<ol>
<li><span class="medCalcFontRef"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18216292" style="color: green; text-decoration: none;" target="_blank">Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model  for chemotherapy-associated thrombosis. Blood 2008; 111:4902.</a></span></li>
<li><span class="medCalcFontRef"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20829374" style="color: green; text-decoration: none;" target="_blank">Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients.  Blood 2010; 116:5377.</a></span></li>
<li><span class="medCalcFontRef"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22052988" style="color: green; text-decoration: none;" target="_blank">Mandala M, Clerici M, Corradino I, et al. Incidence, risk factors and clinical implications of venous  thromboembolism in cancer patients treated within the context of phase I studies:  the 'SENDO experience'. Ann Oncol 2012; 23:1416.</a></span></li>
</ol>
</div>
</form>
</div>
<span class="calculatorVendorId" id="T1678215874">
</span></div><div id="printDisclaimer">
<b>Only digits 0 to 9 and a single decimal point (".") are acceptable as numeric inputs. Attempted input of other characters into a numeric field may lead to an incorrect result.</b>
<p>
	Information on this page may not appear correctly if printed. </p>
</div>
<div id="disclaimerCalculator">
<div class="medCalcFontTwo">
<p class="header">Legal Notices and Disclaimer</p>
<p>
			All information contained in and produced by the EBMcalc system is provided
			for educational purposes only. This information should not be used for the diagnosis or treatment
			of any health problem or disease. 
			<b>THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.</b>
<a class="medCalcDisclaimerLink" href="/legal/ebmcalc-disclaimer">Click here for full notice and disclaimer.</a>
</p>
<p class="copy">EBMcalc is Copyright © 1998-2024 Foundation Internet Services, LLC</p>
</div>
</div><div id="topicVersionRevision">Topic 120626 Version 6.0</div></div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
